Concepedia

Friederike Kanefendt

FK

Statistics

Publications

15

Citations

610

H-Index

12

Active since

2010

Affiliations

Bayer (Germany)(Current)

University of Bonn

Clinical Research Services

University of Cologne

Ospedale Papa Giovanni XXIII

Friederike Kanefendt is an author at Bayer (Germany) specializing in pharmacology, clinical pharmacology, and medicine.

ORCID

Publications per year

2010–2023

15

Publications

15

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

Paola Di Gion, Friederike Kanefendt, Andreas Lindauer et al. · Clinical Pharmacokinetics · 2011 · 217 citations

, , +14

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

Dirk Thomas, Friederike Kanefendt, Stephan Schwers et al. · Journal of Thrombosis and Haemostasis · 2021 · 81 citations · Full text

, , +14

Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study

Dagmar Kubitza, Michael Heckmann, Jana Distler et al. · British Journal of Clinical Pharmacology · 2022 · 65 citations · Full text

, , +13

Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers

Andreas Lindauer, Paola Di Gion, Friederike Kanefendt et al. · Clinical Pharmacology & Therapeutics · 2010 · 56 citations

, , +13

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer

Achim Fritsch, Friederike Kanefendt, JJ Swen et al. · CPT Pharmacometrics & Systems Pharmacology · 2017 · 34 citations · Full text

, , +16

1–5 of 15